Denmark-based Dako has signed an agreement with Genentech, part of the Roche Group, to collaborate on the regulatory submissions of Dako’s HercepTest and HER2 FISH pharmDx as companion diagnostics for a Genentech investigational drug candidate, trastuzumab emtansine (T-DM1), in patients with advanced HER2-positive breast cancer.

Dako and Genentech will collaborate on the regulatory FDA submissions of HercepTest and HER2 FISH pharmDx to identify cancer patients who may be eligible for treatment with the Genentech drug, according to a press release distributed by Dako.

 

The announcement comes on the heels of a recently announced collaboration between the two companies involving the regulatory submissions of HercepTest and HER2 FISH pharmDx as companion diagnostics for another Genentech investigational drug candidate – Pertuzumab.

 

Earlier this year, Dako entered into a collaboration agreement with Amgen Inc. on the development of a diagnostic test for an Amgen cancer drug candidate in clinical development.